The purpose of the trial is to determine how well this combination can shrink or control the disease. Participants receive the injection of epcoritamab and the pill of lenalidomide over several treatment cycles, with regular visits to check health, monitor the cancer’s response, and watch for any side effects. After the treatment period, patients continue to be followed to see how long any benefit lasts and to ensure safety.

The purpose of the trial is to find out whether major adverse cardiovascular event rates are lower in patients who receive the study drug. Participants are randomly assigned to receive either the active drug or placebo, and neither the participants nor the doctors know which one is being taken (double‑blind). The medication is taken once daily, starting before the transplant and continuing for several months, with regular clinic visits for safety checks, blood tests, and heart imaging. Simple explanations are provided for any technical terms: a major adverse cardiovascular event includes serious heart problems such as heart attack or stroke; global longitudinal strain and LVEF are ways doctors measure how well the heart muscle moves and pumps; NT-proBNP and troponin T are blood markers that can indicate heart stress or damage.

One group of participants receives two new medicines, teclistamab and talquetamab, which are given as injections under the skin. The other group receives the already‑approved drug daratumumab, also given by injection, together with the oral pill lenalidomide. All participants continue the assigned therapy for about a year while being checked regularly.

The purpose of the study is to see which maintenance approach is better at achieving a state where no disease can be detected and the patient has a complete response after 12 months. Participants visit the clinic at scheduled intervals for injections, take oral medication as directed, and undergo blood tests and occasional bone‑marrow examinations to determine if the cancer has become undetectable and to monitor safety.

The purpose of the study is to evaluate the impact of Obe-cel on event‑free survival at 12 months. Participants will receive a single infusion of the therapy after a short preparatory regimen, followed by regular clinic visits, blood tests, and bone‑marrow checks over the next two years to see whether the disease returns or any side effects occur. The study records how long patients stay free of disease events, such as relapse or death, and monitors safety.

The purpose of the trial is to evaluate whether the combination of these two medicines is safe and can improve how long the disease stays under control. Participants will first take the oral tablet alone for three treatment cycles, then the injection will be added while the tablet continues, for a total of about two years of therapy. Throughout the study, regular doctor visits, blood tests, and imaging scans will be performed to watch for side effects, check the amount of cancer in the blood and bone marrow, and assess overall health.

The purpose of the study is to find out whether adding hydroxyurea to the rescue regimen is safe and can lead to better outcomes. Participants will receive the set of drugs in several treatment cycles, with infusions given through a vein and oral tablets taken at home. Throughout the treatment period and during follow‑up visits, blood tests and other routine checks will be performed to monitor health and response.

During the trial, doctors will closely watch for side effects such as low blood counts, infections, or organ problems, and will record any signs that the leukemia comes back. The study will measure how many patients stay free of disease for at least one year after starting the combined therapy.

The purpose of the trial is to determine whether daily treatment with Engasertib reduces the frequency of epistaxis compared with placebo over a period of about 28 weeks. Participants will receive either the study drug or placebo each day, keep a simple diary to record each nosebleed event, and attend regular clinic visits where basic health checks and blood work are performed to monitor safety. The study is conducted in a double-blind manner, meaning that neither the participants nor the study staff know which treatment is being taken, which helps ensure unbiased results.

All participants receive the standard drugs in R-mini-CHOP, which include the antibody rituximab and several chemotherapy agents. In the experimental group, patients also receive epcoritamab, which is given as a small injection under the skin (subcutaneous). The standard group receives only the usual chemotherapy and the antibody given either by vein (intravenous) or under the skin, depending on the usual practice.

Participants are randomly assigned to one of the two treatment plans and go through a series of treatment cycles over several months. After the treatment period, regular check‑ups are performed to see whether the cancer has disappeared completely (called complete remission) or whether it has returned. The study follows patients for a period of time after treatment to monitor their health and any side effects.

The study’s purpose is to compare the effect of an oral medicine, mitapivat, with a dummy pill (placebo) on raising hemoglobin levels and to assess its safety in children with this condition.

Children who join will take either the study medicine or the dummy pill once a day for about six months. They will visit the clinic several times, starting with an initial screening, followed by check‑ups at a few weeks and then regularly through week 24. During these visits, blood samples will be taken to measure hemoglobin, iron levels, and other markers, and growth measurements such as height and weight will be recorded. Any side effects or health changes will be monitored throughout the study period.

Participants are randomly assigned to receive either Sapablursen or the placebo, and neither the participants nor the study staff know which treatment is given (double‑blind). Throughout the study, regular blood tests are performed to measure the hematocrit level (the proportion of red blood cells in the blood). If the hematocrit rises above a certain level, a phlebotomy—a simple procedure where a small amount of blood is drawn to lower the count—may be needed. Researchers also ask participants to complete short questionnaires about fatigue and other symptoms to see how the treatment affects daily feeling. The trial lasts roughly 32 weeks, with visits scheduled at regular intervals to monitor safety, any side effects, and overall health.

The aim is to see whether the drug can lower the amount of blood that must be given compared with the placebo. The trial is a phase 3 study that is double‑blind (neither the children nor the doctors know which treatment is given) and randomized (children are assigned to one group or the other by chance). The study also looks at how the drug moves through the body (pharmacokinetics) and whether it is safe.

Children will be screened, then start taking the study medication for about a year, with regular clinic visits to check blood counts, transfusion records, iron levels, growth, and bone health. Blood tests will be done to monitor for any side effects, to measure drug levels, and to assess changes in iron overload, a condition where excess iron builds up in the body. The study ends after the last visit, when all data are collected.

The purpose of the study is to determine which treatment approach provides a longer-lasting increase in platelet levels. Participants are assigned by chance to one of the two treatment groups and receive the assigned medication for several weeks. Throughout the study, regular blood tests are performed to check platelet counts, and participants attend clinic visits to monitor their health and any side effects.

The study flow includes an initial screening, the start of the assigned therapy, periodic follow‑up visits for blood sampling and safety checks, and a final assessment at the end of the treatment period. Any serious or unexpected problems are recorded, and the overall safety of the medications is closely observed.

The purpose of the study is to determine whether the infusion of this engineered cell therapy can be administered safely and is feasible for further testing.

Participants who meet the study requirements will first undergo a screening process to confirm eligibility. Those who proceed will receive a single infusion of the cell therapy, after which they will be monitored closely for at least four weeks for any side effects and for early signs that the cancer may be responding. Follow‑up visits continue for several months, during which blood tests and other routine examinations are performed to track safety and any changes in the disease.

The purpose of the trial is to compare the effectiveness and safety of the reduced‑dose regimen with the standard regimen. Participants will be randomly placed into one of the two dosing groups and will receive treatment cycles that include the three medicines given on a regular schedule, with visits for blood work, bone‑marrow testing, and eye examinations to monitor for problems such as blurry vision or damage to the surface of the eye. Throughout the study, doctors will also check for MRD, which stands for minimal residual disease and means looking for very small numbers of cancer cells that may remain after treatment. The study continues for several months, with regular check‑ups to assess how well the cancer is responding and to record any side effects.

Participants receive a combination of chemotherapy drugs that are standard for this disease, given either through a vein or by mouth. The chemotherapy includes methotrexate, cyclophosphamide, mercaptopurine, vinorelbine, pegaspargase, cytarabine, dexamethasone, tioguanine, recombinant l-asparaginase, and doxorubicin. In the experimental part, patients also receive a short course of the targeted immunotherapy drug blinatumomab, which helps the immune system recognize and attack leukemia cells. Treatment is given in several cycles over a few months, followed by regular check‑ups to monitor health, any side effects, and whether the disease returns, while recording disease‑free survival, overall survival, hospital stay length, and quality of life.

The purpose is to determine whether adding this drug lowers the level of a blood protein called calprotectin after three months compared with standard treatment alone. Participants will have blood samples taken and complete short questionnaires at the start of the study, at three months, and at six months, and they will record each dose taken in a simple diary. Safety will be monitored by checking for any side effects throughout the study period.

Participants will receive the injection at set times over several months and will visit the clinic for regular check‑ups, blood tests, and simple questionnaires about symptoms. Researchers will watch for any unwanted effects, measure the amount of drug in the blood, and track changes in eosinophil levels. The study also includes groups of children with specific forms of the condition, such as EGPA and HES, to see if the drug helps keep the disease in remission (meaning symptoms are minimal or absent) and to record any relapses or flares (times when symptoms get worse). All information gathered will help determine whether benralizumab can be used safely and effectively in this young population.

Participants will take the oral medication daily, with the dose gradually increased at the start of treatment, and will receive the infusion drug on scheduled days during the first few months. Regular clinic visits will include blood tests and imaging to monitor disease status, and a special laboratory test called MRD (minimal residual disease) will be used to determine whether cancer cells are below a very low threshold. The study also examines how genetic factors such as TP53 deletion or mutation, the IGHV gene condition, and the protein marker CD38 influence outcomes; these are assessed with techniques like FISH (a test that looks at chromosomes) and NGS (a method that reads DNA sequences). Patients will complete quality‑of‑life questionnaires throughout the study, and the overall treatment experience, including any hospital stays, will be recorded.

Participants may receive one of several study medicines: an oral tablet called ibrutinib, an oral capsule named zanubrutinib, an intravenous infusion of linvoseltamab, a subcutaneous injection (under the skin) of elranatamab, a subcutaneous injection of teclistamab, or a subcutaneous injection of talquetamab. Oral medicines are taken by mouth, while the infusion is given through a vein and the injections are placed just under the skin. Each medication is given at a specific dose that is determined by the study plan.

People are randomly assigned to receive one of the medicines and are followed for a period of time with regular clinic visits, blood tests, and health questionnaires. Throughout the study, researchers track how long participants live (called overall survival) and other health outcomes such as disease progression and quality of life, while also monitoring for any side effects.

The study aims to assess whether the new medicine is safe and works better than the standard drug in preventing new clots and serious bleeding. Participants are first observed for safety after receiving the test drug, and later are randomly assigned to receive either the test drug or the standard drug for several months while doctors watch for any new clot events or bleeding problems.

During the trial, participants will take the assigned medication by injection or by mouth according to a schedule set by the study team, and they will attend regular clinic visits where simple blood tests and scans may be performed to check how well the blood is clotting and to look for any side effects. All health information is recorded, and any problems are treated promptly.